23 February 2026
23 February 2026
The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.
Three new board and shareholder-elected members could join Novo’s council, which largely consists of recent appointees following a restructure in October 2025.
AMPLIFY Phase III data showed 77% on Calquence plus venetoclax were progression free at three years.
The biotech, which is co-run by ex US Health Secretary Brett Giroir, will progress its COPD-centric anti-rhinoviral therapy to mid-stage trials.
The FDA decision is anticipated by 18 December 2026.
Analysis by WHO estimates that 6.2 million lives could be saved if next-generation vaccines are used through to 2050.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
